Core Viewpoint - The acquisition of Shanghai Siyuanli Industrial Co., Ltd. by Meili Tianyuan Medical Health is a strategic move to reshape the competitive landscape of the high-end beauty industry in China's high-tier cities, following the successful acquisition of Nairui in 2024 [1][3]. Group 1: Acquisition Details - Meili Tianyuan Medical Health and its subsidiaries have agreed to acquire 100% of the issued shares of Shanghai Siyuanli for a consideration of RMB 1.25 billion [1]. - The acquisition will involve the issuance of 15.7981 million shares to SYL Holding, representing approximately 6.70% of the total issued shares as of the announcement date [1]. Group 2: Target Company Overview - Shanghai Siyuanli, established on December 31, 2009, is a leading brand in China's high-end beauty service industry, focusing on skincare products and professional beauty experiences for women in high-tier cities [2]. - As of June 30, 2025, the target company operates 163 beauty stores and 19 medical beauty clinics across 48 cities in China, with over 90% of its revenue coming from stores in the top 20 first-tier and new first-tier cities [2]. Group 3: Strategic Implications - The acquisition is expected to significantly expand the store network to 734 locations, enhancing the customer base and market share of Meili Tianyuan [3]. - The integration will leverage five core capabilities, including chain management, customer lifecycle management, medical service upgrades, AI transformation, and supply chain integration, to maximize synergies and drive revenue and profit growth [3].
美丽田园医疗健康(02373.HK)拟12.5亿元收购上海思妍丽实业100%股权，加速布局高端美容市场